EASL update guidelines for hepatitis C (April 2014)

Responding promptly to the approval of new drugs in the EU, this update is notable no longer requiring separate management guidelines for HIV positive people who are coinfected with hepatitis C, based on efficacy and safety of DAAs, though this is dependent on access to DAAs.

Treatment options using sofosbuvir, simeprevir and declatasvir – now all approved or available in the EU – are given by HCV genotype. (PDF)

Links to other websites are current at date of posting but not maintained.